Procter & Gamble Co (NYSE: PG) appears poised for top-line growth. Jefferies’ Kevin Grundy initiated coverage of the company with a Buy rating and a price target of $95. The analyst expects the company to generate organic sales growth of 3.5 percent by FY18, which is in-line with the industry, but ahead of the expectation of ~2.5-3 percent.

Procter & Gamble’s organic sales growth is expected to be driven by its “slimmed down portfolio, better focused on geos/categories where it can (and should) win,” analyst Kevin Grundy said. An inflection in organic sales and EPS upside are likely to act as catalysts for the company’s shares.

“P&G has shed 15%/5% of sales/profits, streamlined its portfolio, and continues to rationalize its cost structure. While now better positioned to win, an inability to improve org sales trends and/or TSR (P&G has underperformed the XLP in 8 of last 10 years) likely will (and should) lead to further changes,” the analyst wrote.